Skip to main content

The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics

8Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Although it is well established that funding source influences the publication of clinical trials, relatively little is known about how funding influences trial design. We examined a public trial registry to determine how funding source shapes trial design among trials involving antihyperlipidemics. We used an automated process to identify and analyze 809 trials from a set of 72,564. Three networks representing industry-, collaboratively, and non-industry-funded trials were constructed. Each network comprised 18 drugs as nodes connected according to the number of comparisons made between them. The results indicated that industry-funded trials were more likely to compare across drugs and examine dyslipidemia as a condition, and less likely to register safety outcomes. The source of funding for clinical trials had a measurable effect on trial design, which helps quantify differences in research agendas. Improved monitoring of current clinical trials may be used to more closely align research agendas to clinical needs. © 2012 American Society for Clinical Pharmacology and Therapeutics.

Cite

CITATION STYLE

APA

Dunn, A. G., Bourgeois, F. T., Murthy, S., Mandl, K. D., Day, R. O., & Coiera, E. (2012). The role and impact of research agendas on the comparative-effectiveness research among antihyperlipidemics. Clinical Pharmacology and Therapeutics, 91(4), 685–691. https://doi.org/10.1038/clpt.2011.279

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free